HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer Meeting Abstract
| Authors: | Hurvitz, S.; Vahdat, L.; Harbeck, N.; Wolff, A. C.; Tolaney, S. M.; Loi, S.; Masuda, N.; O'Shaughnessy, J.; Dong, C.; Walker, L.; Rustia, E.; Borges, V. F. |
| Abstract Title: | HER2CLIMB-02: A randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer |
| Meeting Title: | 43rd Annual San Antonio Breast Cancer Symposium (2020 SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 81 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2020 Dec 8-11 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2021-02-01 |
| Language: | English |
| ACCESSION: | WOS:000618737700095 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.SABCS20-OT-28-01 |
| Notes: | Meeting Abstract: OT-28-01 -- This symposium was held virtually due to COVID-19 -- Source: Wos |
